In a tough funding environment, some biotechs are choosing to leave executive positions vacant and either spread responsibilities or find a part-time leader.
There is growing investment in fighting bacterial growth in a wide range of settings, with the market estimated to reach more than $3 billion within eight years.
Continued fallout from the IRA, heightened antitrust enforcement and the rise of AI will all shape the first wave of biotech mergers and acquisitions coming this year, experts tell BioSpace.
